Small Cell Lung Cancer Clinical Trials 2018

Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove.

Small cell lung cancer clinical trials 2018.

Histologic or cytologic confirmed diagnosis of small cell lung cancer either limited or extensive disease at initial presentation is allowed. Treatment patterns in advanced small cell lung cancer sclc the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The clinical trials on this list are for small cell lung cancer treatment. N engl j med.

Clinical trials look at new ways to prevent detect or treat disease. However a phase 2 single group study of maintenance pembrolizumab and. Nci s basic information about clinical trials explains the types and phases of trials and how they are carried out. For the first time in more than two decades a treatment has been shown to improve how long patients with advanced small cell lung cancer sclc live.

All trials on the list are supported by nci. The efficacy and safety. Clinical trials are research studies that involve people. Listing a study does not mean it has been evaluated by the u s.

In a large clinical trial treatment with the immunotherapy drug atezolizumab tecentriq combined with a standard chemotherapy regimen increased survival in patients with this highly aggressive form of lung cancer. At least 1 prior regimen must have contained a platinum salt adjuvant therapy will constitute a prior treatment. Evidence of progressive disease during or following 1 or 2 prior chemotherapy regimens. Consolidative radiotherapy for limited metastatic non small cell lung cancer.

First line atezolizumab plus chemotherapy in extensive stage small cell lung cancer. In addition this website offers free access to a video based educational program about cancer clinical trials located outside of this guide. A phase 2 randomized clinical trial jama oncol. Epub 2018 sep 25.

Use the menu to choose a different section to read in this guide. The next section in this guide is latest research. In this commentary we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer discuss challenges faced by regulatory agencies and highlight paradoxical lessons that emerge.